{"schemaVersion":1,"research":true,"symbol":"vtrs","name":"Viatris","topic":"moat","path":"/stock/vtrs/moat","status":"published","version":4,"updatedAt":"2026-10-18T00:39:27.525Z","locked":false,"publicFairValue":false,"fairValue":null,"moat":{"verdict":"none","summary":"The supplied disclosures establish realized competitive weakness rather than a durable company-wide moat. Generic competition has caused price cuts and volume losses, tenders continue to hurt sales, and consolidated buyers constrain pricing. Product protection and development capabilities offer limited advantages, but pipeline success remains potential rather than demonstrated commercial durability. Improved quarterly gross margins provide evidence of operating resilience, not proof of pricing power or a structural cost advantage.","advantages":[{"mechanism":"intangible_assets","claim":"Product-specific intellectual property and regulatory protection can temporarily shelter selected branded products. The passages do not demonstrate protection sufficiently broad or durable to establish a Viatris moat; positive clinical results support future potential.","durability":"Protection is finite and exposed to litigation and generic entry. The August 2026 filing identifies possible Amitiza generic entry in Japan in December 2026, contingent on litigation, updating the earlier June 2026 exclusivity warning.","risks":"Aggressive generic pricing has already caused branded-product price cuts and volume losses in China. Clinical success does not establish approval, commercial adoption or durable pricing.","invalidation":"The limited protection thesis would fail for affected products if generic entry produces sustained price and volume erosion. The company-wide no-moat conclusion should be reconsidered if protected launches demonstrate sustained demand and pricing through competitive entry, with supply continuity and evidence that the advantage extends beyond isolated products.","competitors":[],"evidenceIds":["e1","e2","e3"],"counterEvidenceIds":["e4","e5","e6"]}],"evidence":[{"id":"e1","sourceId":"filing-1","location":"Risk factors: competition affecting patent-protected and branded products","excerpt":"As we focus on developing or acquiring innovative, best-in-class, patent-protected assets, competition from manufacturers of generic or biosimilar drugs, including from generic versions of competitors’ branded products that lose their market exclusivity, has been and will continue to be a major challenge for our patent-protected and branded products."},{"id":"e2","sourceId":"filing-1","location":"2025 accomplishments: meloxicam Phase 3 endpoints","excerpt":"In both Phase 3 studies, all primary and key secondary endpoints were met and MR-107A-02 demonstrated statistically significant and clinically meaningful results."},{"id":"e3","sourceId":"filing-2","location":"MD&A: possible Amitiza generic entry in Japan","excerpt":"For example, generic entry for Amitiza® 24 μg may occur in Japan in December 2026 depending on the outcome of patent litigation."},{"id":"e4","sourceId":"filing-1","location":"Risk factors: realized branded-product price cuts and volume loss in China","excerpt":"In China, for example, we face strong competition from certain generic manufacturers, which has resulted and may in the future result in price cuts and volume loss on some of Viatris’ branded products without patent term and/or regulatory protection."},{"id":"e5","sourceId":"filing-2","location":"MD&A: continuing negative tender impact on sales","excerpt":"Sales continue to be negatively affected by the impact of tender systems in certain countries."},{"id":"e6","sourceId":"filing-1","location":"Risk factors: authorization of multiple generics in Europe","excerpt":"The European Commission or national regulatory agencies may grant marketing authorizations to any number of generics."},{"id":"e7","sourceId":"filing-1","location":"Item 1 Business: management assertion concerning breadth and scale","excerpt":"Viatris Charter Amended and restated certificate of incorporation of Viatris Inc., as amended WHO World Health Organization YEN Term Loan Facility The ¥40 billion term loan agreement dated as of July 1, 2021, among Viatris, the guarantors from time to time party thereto, the lenders from time to time party thereto and Mizuho Bank, Ltd., as administrative agent 7 Table of Contents PART I ITEM 1.Business About Viatris Viatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally."},{"id":"e8","sourceId":"filing-1","location":"Risk factors: customer consolidation and increased purchasing leverage","excerpt":"This consolidation has resulted in these groups gaining additional purchasing leverage and, consequently, increasing the product pricing pressures facing our business."},{"id":"e9","sourceId":"filing-1","location":"Risk factors: sales concentration among wholesalers and retail chains","excerpt":"In addition, a significant amount of our sales are to a relatively small number of drug wholesalers and retail drug chains."},{"id":"e10","sourceId":"filing-2","location":"MD&A: manufacturers establish tender prices through bids","excerpt":"Under such tender systems, manufacturers submit bids that establish prices for generic pharmaceutical products."},{"id":"e11","sourceId":"filing-2","location":"MD&A: tender underbidding","excerpt":"The tender system often results in companies underbidding one another by proposing lower pricing in order to win the tender."},{"id":"e12","sourceId":"filing-2","location":"MD&A: implemented government price reductions","excerpt":"have undergone government-imposed price reductions, and further government-imposed price reductions are expected in the future."},{"id":"e13","sourceId":"filing-2","location":"Quarterly results: second-quarter 2026 gross profit and margin","excerpt":"Gross profit for the three months ended June 30, 2026 was $1.46 billion and gross margins were 39%."},{"id":"e14","sourceId":"filing-2","location":"Quarterly results: second-quarter 2025 gross profit and margin","excerpt":"For the three months ended June 30, 2025, gross profit was $1.33 billion and gross margins were 37%."},{"id":"e15","sourceId":"filing-2","location":"Quarterly results: product mix explanation for gross margin changes","excerpt":"The changes in gross profit and gross margins are primarily driven by product mix."},{"id":"e16","sourceId":"filing-2","location":"Quarterly results: comparative adjusted gross margins","excerpt":"Adjusted gross margins were approximately 57% for the three months ended June 30, 2026, compared to approximately 57% for the three months ended June 30, 2025."},{"id":"e17","sourceId":"filing-2","location":"Manufacturing disruption: inventory, fixed-asset and manufacturing charges","excerpt":"During the three and six months ended June 30, 2026, the Company recognized total charges of $14.9 million and $86.8 million, respectively, within Cost of Sales in the condensed consolidated statements of operations primarily related to the write off of inventory and fixed assets damaged in the fire and incremental manufacturing variances."},{"id":"e18","sourceId":"filing-2","location":"Manufacturing disruption: resumed production and expected supply impact","excerpt":"While production at the facility has resumed, the temporary manufacturing suspension due to the fire at the facility in February along with these intermittent disruptions are expected to impact product supply in the second half of the year."},{"id":"e19","sourceId":"filing-1","location":"Mapi investment: full impairment following regulatory and commercial uncertainty","excerpt":"As a result of the uncertainty of regulatory and commercial timing and success of GA Depot and the financial condition of Mapi, the Company fully impaired its equity investment and prepaid assets related to advances for the initial supply of commercial product."},{"id":"e20","sourceId":"filing-1","location":"Mapi investment: recorded 2024 charges","excerpt":"Total charges of $184.6 million were recorded during the year ended December 31, 2024 as a component of Other Expense (Income), Net in the consolidated statements of operations."},{"id":"e21","sourceId":"filing-2","location":"Share repurchases: completed second-quarter 2026 purchases","excerpt":"During the three months ended June 30, 2026, the Company repurchased approximately 9.4 million shares of common stock at a cost of approximately $150.0 million under this program."},{"id":"e22","sourceId":"filing-3","location":"Shareholder letter: reported 2025 capital returns","excerpt":"We prioritized capital return with more than $1 billion returned to shareholders through dividends and share repurchases."},{"id":"e23","sourceId":"filing-3","location":"Compensation discussion: relative TSR modifier and ownership requirements","excerpt":"We aligned executive compensation with shareholder interests by linking pay to the Company’s stated strategic priorities, long-term performance, and share price appreciation, including through the use of a relative TSR modifier for PRSUs in our long-term incentive plan and robust share ownership requirements."},{"id":"e24","sourceId":"filing-3","location":"Compensation policies: adopted 2025 ownership-guideline change","excerpt":"During 2025, our Compensation Committee strengthened our required executive share ownership guidelines by no longer counting unvested PRSUs and corresponding dividend equivalent units toward ownership thresholds."},{"id":"e25","sourceId":"filing-3","location":"Compensation policies: executive ownership multiples","excerpt":"Position Ownership Requirement Chief Executive Officer 6x Chief Financial Officer 3x Other NEOs 3x In addition to the NEOs, the Viatris share ownership policy covers the most senior employees at Viatris determined by reference to position grade to promote an ownership culture and further align the interests of those leaders with those of shareholders."},{"id":"e26","sourceId":"filing-3","location":"Compensation policies: securities counted toward ownership compliance","excerpt":"Common stock actually owned by the covered employee (including shares of common stock held by the covered employee in the Restoration Plan), as well as restricted shares and unvested RSUs (including corresponding “DEUs”) count toward compliance with these requirements."},{"id":"e27","sourceId":"filing-3","location":"Compensation policies: qualified statement of ownership compliance","excerpt":"All NEOs meet these share ownership requirements or are expected to meet them by the applicable date."},{"id":"e28","sourceId":"filing-3","location":"Board governance: independent committee composition","excerpt":"The Audit, Compensation, Compliance and Risk Oversight, Executive, Finance, and Governance and Sustainability Committees are composed entirely of independent Directors (as defined in the applicable NASDAQ listing rules and applicable SEC rules)."},{"id":"e29","sourceId":"filing-3","location":"Board governance: independent chair authority","excerpt":"The independent Chair determines the information sent to the Board, the Board’s meeting agendas, and meeting schedules to assure that the Board is properly informed with respect to agenda items in advance and that there is sufficient time for discussion of agenda items at the meetings."},{"id":"e30","sourceId":"filing-3","location":"Compensation governance: approved clawback policy","excerpt":"Clawback Policy The Board has approved a clawback policy relating to incentive compensation programs."},{"id":"e31","sourceId":"filing-1","location":"Intellectual property: Biogen and European dimethyl fumarate launch","excerpt":"Dimethyl Fumarate The Company launched its generic dimethyl fumarate (“DMF”) product in Europe starting in July 2022 after the European Commission concluded that Biogen was not entitled to regulatory data exclusivity for Tecfidera®."},{"id":"e32","sourceId":"filing-1","location":"Intellectual property: February 2026 denial of authorization-revocation challenge","excerpt":"The Company challenged the European Commission’s revocation decision before the General Court of the European Union (“GCEU”) and, in February 2026, the GCEU denied the Company’s challenge."}],"changes":["No comparable previous version."],"limitations":["Assessment uses only supplied issuer passages. Source dates are filing dates: February 26, April 2 and August 6, 2026; they are not retrieval dates.","The passages identify Biogen in the specific dimethyl fumarate dispute, but do not establish broad named-competitor coverage. Competitors affecting the claimed branded-product advantage are described generically, so its competitor array is empty.","Management's breadth-and-scale assertion does not demonstrate lower unit costs than competitors. No durable network effect, customer switching barrier or efficient-scale market structure is established.","No quantified customer retention, product-level pricing bridge or comprehensive patent-duration schedule is supplied. Retention is assessed indirectly from disclosed volume loss and buyer leverage.","Capital returns and impairments are disclosed, but comprehensive cash generation, leverage, acquisition returns and net dilution evidence are missing. Repurchases alone do not establish value creation.","The proxy supplies actual compensation and governance policies, but not sufficient individual beneficial ownership, realized incentive outcomes or evidence of exceptional governance effectiveness. Its statement that executives meet or are expected to meet ownership requirements does not establish that every executive already complies.","Generic risk possibilities are distinguished from realized price cuts, tender effects and manufacturing charges. Short comparative margin periods cannot establish long-term resilience."],"qualityAssessments":[{"category":"moat","checks":[{"criterion":"structural_advantage","grade":1,"rationale":"Selected product protections offer limited shelter, but realized generic pressure and authorization of multiple competing generics outweigh the unsupported claim that scale creates a structural advantage.","evidenceIds":["e1","e4","e6","e7"]},{"criterion":"durability","grade":1,"rationale":"Protection is product-specific and finite; possible Amitiza entry and the failed European authorization challenge illustrate erosion. Clinical endpoints establish development progress rather than durable commercial protection.","evidenceIds":["e2","e3","e31","e32"]},{"criterion":"customer_dependency","grade":1,"rationale":"Observed volume loss and increased buyer leverage indicate weak supplier indispensability. This assessment uses indirect operating evidence; the passages do not quantify switching costs or customer retention.","evidenceIds":["e4","e8","e9"]},{"criterion":"erosion_resilience","grade":1,"rationale":"Tender-related sales weakness and branded-product price and volume erosion persist. Stable adjusted quarterly margins provide a partial offset, while manufacturing disruption exposes another vulnerability.","evidenceIds":["e4","e5","e16","e17","e18"]}]},{"category":"pricing_power","checks":[{"criterion":"realized_pricing","grade":0,"rationale":"Actual branded-product price cuts in China and implemented government reductions directly establish adverse pricing outcomes. Continuing tender effects reinforce the weakness; market-wide extreme bid cuts are not treated as Viatris-specific reductions.","evidenceIds":["e4","e5","e12"]},{"criterion":"retention","grade":1,"rationale":"Disclosed branded-product volume losses and tender-related sales pressure suggest fragile demand retention under competition. This is an indirect assessment, without a fabricated retention rate.","evidenceIds":["e4","e5"]},{"criterion":"margin_resilience","grade":2,"rationale":"Second-quarter GAAP gross margin improved from 37% to 39%, primarily through mix, while adjusted margin remained approximately 57%. Manufacturing charges temper this resilience, and these outcomes do not establish pricing power.","evidenceIds":["e13","e14","e15","e16","e17"]},{"criterion":"contractual_freedom","grade":1,"rationale":"Viatris can submit tender bids, but underbidding, government price reductions and powerful consolidated buyers substantially constrain practical price-setting freedom.","evidenceIds":["e8","e10","e11","e12"]}]},{"category":"strong_management","checks":[{"criterion":"capital_discipline","grade":2,"rationale":"Completed capital returns demonstrate deployment discipline in a limited sense, while the $184.6 million Mapi-related charges show an investment setback. Missing cash-flow, financing and investment-return detail prevents a stronger assessment.","evidenceIds":["e19","e20","e21","e22"]},{"criterion":"incentive_alignment","grade":2,"rationale":"Disclosed TSR linkage, ownership multiples and the adopted exclusion of unvested performance awards support alignment. Unvested RSUs still count, compliance wording is qualified, and realized pay-performance outcomes are absent.","evidenceIds":["e23","e24","e25","e26","e27"]},{"criterion":"execution","grade":2,"rationale":"Positive Phase 3 endpoints and comparative gross-profit improvement demonstrate progress, balanced by realized manufacturing losses, supply disruption and the Mapi impairment. Commercial execution is assessed partly from indirect operating results rather than management's characterization.","evidenceIds":["e2","e13","e14","e17","e18","e19"]},{"criterion":"governance","grade":2,"rationale":"Independent committee composition, substantive independent-chair authority and an approved clawback policy establish concrete governance safeguards. Their effectiveness and sustained accountability outcomes are not demonstrated by the supplied passages.","evidenceIds":["e28","e29","e30"]}]}],"qualityPolicy":"quality-scores-2","basisHash":"e76b32ee39509774aac87b69859737dc91728017fe78233bf97b11ed08d5a395","updatedAt":"2026-10-18T00:39:27.525Z","sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/vtrs-20251231.htm","publishedAt":"2026-02-26","sha256":"1aa3f7e146cdb9ec634fe325f5df28845f2120dfd9c81a74d6812284a559e7f6","dateKind":"filed"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/1792044/000179204426000041/vtrs-20260630.htm","publishedAt":"2026-08-06","sha256":"637e6e59f21c495328189d57005634f783ee633c5b920b79ebaa55dbc13d3f0f","dateKind":"filed"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/1792044/000114036126013002/ny20062029x771_def14a.htm","publishedAt":"2026-04-02","sha256":"402a1ee724a0f1c82b93858d6e02b3907a353ac6371fdd77e0e6b91ba6c2047f","dateKind":"filed"}],"model":"gpt-6.1-sol","providerId":"codex:54ed50707940d2fb3ba85062952878e4ae12cec63a708523725cdbd09a045cec","usage":{"input_tokens":49668,"cached_input_tokens":20992,"cache_write_input_tokens":0,"output_tokens":3402,"reasoning_output_tokens":156},"basisSupplement":{"previousHash":"78d7aa79a2eeb11939da2357f8879e58fe34bc9cd4aa79089f7d6c7c1a62e332","checkedAt":"2026-10-18T16:49:32.080Z","rule":"dated historical and missing inputs only; accepted observations and research date retained"}},"signals":[{"period":"2021","end":"2021-12-31","values":{"gross_margin":31.299119773656088,"operating_margin":-0.19086540620649392,"roic":null,"fcf_margin":14.369358243140077,"sbc_revenue":0.6242421520635919},"issues":{"pe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","peg":"Two complete TTM earnings bases and their diluted share counts are required for year-over-year growth.","pb":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","earnings_yield":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic":"NOPAT is undefined under this method: pretax profit must be positive and the effective tax rate must be between 0 and 100%.","roiic":"Invested capital did not increase versus the prior year. ROIIC requires a positive increase.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}},{"period":"2022","end":"2022-12-31","values":{"gross_margin":40.06017967579433,"operating_margin":9.957393282813646,"roic":2.9664435697093747,"fcf_margin":15.702209260024294,"sbc_revenue":0.7177166252520333},"issues":{"pe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","peg":"Two complete TTM earnings bases and their diluted share counts are required for year-over-year growth.","pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pb":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","earnings_yield":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roiic":"Invested capital did not increase versus the prior year. ROIIC requires a positive increase.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}},{"period":"2023","end":"2023-12-31","values":{"gross_margin":41.84060721062619,"operating_margin":4.979075147513711,"roic":0.5387852630280039,"fcf_margin":15.743027215305036,"sbc_revenue":1.1742611317615865},"issues":{"pe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","peg":"Two complete TTM earnings bases and their diluted share counts are required for year-over-year growth.","pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pb":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","earnings_yield":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roiic":"Invested capital did not increase versus the prior year. ROIIC requires a positive increase.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}},{"period":"2024","end":"2024-12-31","values":{"gross_margin":38.2745290210171,"operating_margin":0.0687411521289339,"roic":null,"fcf_margin":13.45488946967222,"sbc_revenue":0.9943645867363607},"issues":{"pe":"Diluted share count is unavailable in the extracted statements for this period.","peg":"Two complete TTM earnings bases and their diluted share counts are required for year-over-year growth.","ps":"Diluted share count is unavailable in the extracted statements for this period.","pfcf":"Diluted share count is unavailable in the extracted statements for this period.","pfcf_growth":"Two complete TTM FCF bases and their diluted share counts are required for year-over-year growth.","pocf":"Diluted share count is unavailable in the extracted statements for this period.","pb":"Diluted share count is unavailable in the extracted statements for this period.","fcf_yield":"Diluted share count is unavailable in the extracted statements for this period.","earnings_yield":"Diluted share count is unavailable in the extracted statements for this period.","ev_sales":"Diluted share count is unavailable in the extracted statements for this period.","ev_ebitda":"Diluted share count is unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic":"NOPAT is undefined under this method: pretax profit must be positive and the effective tax rate must be between 0 and 100%.","roiic":"Invested capital did not increase versus the prior year. ROIIC requires a positive increase.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","diluted_shares":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","basic_shares":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","dilution":"The reported inputs required for this metric are unavailable in the extracted statements for this period."}},{"period":"2025","end":"2025-12-31","values":{"gross_margin":35.18146859035536,"operating_margin":-18.687896480098804,"roic":null,"fcf_margin":13.593302644136307,"sbc_revenue":1.2469825408409587},"issues":{"pe":"Diluted share count is unavailable in the extracted statements for this period.","peg":"Two complete TTM earnings bases and their diluted share counts are required for year-over-year growth.","ps":"Diluted share count is unavailable in the extracted statements for this period.","pfcf":"Diluted share count is unavailable in the extracted statements for this period.","pfcf_growth":"Two complete TTM FCF bases and their diluted share counts are required for year-over-year growth.","pocf":"Diluted share count is unavailable in the extracted statements for this period.","pb":"Diluted share count is unavailable in the extracted statements for this period.","fcf_yield":"Diluted share count is unavailable in the extracted statements for this period.","earnings_yield":"Diluted share count is unavailable in the extracted statements for this period.","ev_sales":"Diluted share count is unavailable in the extracted statements for this period.","ev_ebitda":"Diluted share count is unavailable in the extracted statements for this period.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic":"NOPAT is undefined under this method: pretax profit must be positive and the effective tax rate must be between 0 and 100%.","roiic":"Invested capital did not increase versus the prior year. ROIIC requires a positive increase.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","diluted_shares":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","basic_shares":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","dilution":"The reported inputs required for this metric are unavailable in the extracted statements for this period."}}],"sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/vtrs-20251231.htm","publishedAt":"2026-02-26","sha256":"1aa3f7e146cdb9ec634fe325f5df28845f2120dfd9c81a74d6812284a559e7f6","dateKind":"filed"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/1792044/000179204426000041/vtrs-20260630.htm","publishedAt":"2026-08-06","sha256":"637e6e59f21c495328189d57005634f783ee633c5b920b79ebaa55dbc13d3f0f","dateKind":"filed"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/1792044/000114036126013002/ny20062029x771_def14a.htm","publishedAt":"2026-04-02","sha256":"402a1ee724a0f1c82b93858d6e02b3907a353ac6371fdd77e0e6b91ba6c2047f","dateKind":"filed"}],"history":[{"version":4,"updatedAt":"2026-10-18T16:49:32.080Z","verdict":"none","value":null},{"version":3,"updatedAt":"2026-10-18T16:35:43.872Z","verdict":"none","value":null},{"version":2,"updatedAt":"2026-10-18T02:27:49.793Z","verdict":"none","value":null},{"version":1,"updatedAt":"2026-10-18T02:18:02.026Z","verdict":null,"value":null}],"hasRequested":false,"requestStatus":"completed","researchIssue":null,"archivedMoat":null,"scope":"supported_catalog"}